The probiotics with the most research behind them for urinary tract infections are specific strains of Lactobacillus, particularly L. crispatus CTV-05, L. rhamnosus GR-1, and L. reuteri RC-14. That said, the evidence is promising but not definitive. Probiotics are better supported for preventing recurrent UTIs than for treating an active infection, which still requires antibiotics.
The Strains That Matter Most
Not all probiotics are interchangeable. The strain printed on the label matters far more than the species name, and only a handful of strains have been tested in clinical trials for UTI prevention.
Lactobacillus crispatus CTV-05 has some of the strongest individual trial results. In a placebo-controlled trial of premenopausal women prone to recurrent UTIs, 15% of women using an intravaginal L. crispatus suppository had a UTI recurrence, compared with 27% of women on placebo. That’s roughly half the risk. Even more striking: women who achieved high levels of vaginal colonization with this strain had a 93% reduction in recurrence risk. The catch is that this strain is delivered vaginally, not orally, and isn’t widely available as an over-the-counter product.
Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14 are the most studied oral combination. A systematic review of trials in women concluded this pairing was effective for preventing recurrent UTIs when taken either orally or vaginally. In one 12-month trial of postmenopausal women, the combination reduced the average number of symptomatic UTIs, though it didn’t perform quite as well as a standard preventive antibiotic. Results in other populations have been less clear. A trial in people with spinal cord injuries found no significant benefit from this combination, though a post-hoc analysis hinted at a possible protective effect when the strains were used alone.
How These Probiotics Protect Against UTIs
Most UTIs are caused by E. coli bacteria migrating from the gut or vaginal area into the urinary tract. Lactobacillus strains fight back through several mechanisms. They produce lactic acid and hydrogen peroxide, both of which directly inhibit E. coli growth and put the bacteria under stress. More importantly, these compounds reduce E. coli’s ability to stick to the walls of the urinary tract by suppressing the production of tiny hair-like structures (called fimbriae) that the bacteria use to latch on. If E. coli can’t attach, it gets flushed out before it can cause an infection.
This is also why vaginal delivery tends to show stronger results. The urinary tract and vagina share similar tissue, and Lactobacillus species naturally dominate a healthy vaginal environment. When that balance is disrupted, whether by antibiotics, hormonal changes, or other factors, E. coli has an easier path to the bladder.
Oral vs. Vaginal Delivery
A randomized trial comparing oral probiotics, vaginal probiotics, a combination of both, and placebo found a clear pattern. Women using vaginal probiotics had a UTI incidence of about 41% over four months, and those using the combination of oral and vaginal had an incidence of about 32%. Both were significantly better than placebo (70%) and oral-only probiotics (61%). The time to first UTI recurrence also roughly doubled in the vaginal and combination groups, averaging 124 to 142 days compared with about 70 days for placebo or oral-only groups.
Oral probiotics on their own showed a more modest effect. They can still colonize the vaginal tract after passing through the digestive system, but the process is less direct and less reliable. If you’re choosing between the two, vaginal delivery has better evidence. Combining both routes may offer a slight additional benefit.
What the Overall Evidence Shows
A Cochrane review, considered the gold standard for evaluating medical evidence, pooled six studies involving 352 women and children. It found that probiotics reduced UTI recurrence by about 18% compared to placebo, but this result wasn’t statistically significant. The confidence interval ranged from a meaningful 16% absolute decrease to a small 5% increase in risk, meaning the true effect could fall anywhere in that range. The quality of evidence was rated low.
This doesn’t mean probiotics don’t work. It means the trials so far have been small, used different strains and doses, and followed patients for varying lengths of time. The most consistent results come from specific well-studied strains at adequate doses, not from generic “women’s health” probiotic blends. A general Lactobacillus supplement from the pharmacy shelf may contain entirely different strains than those tested in UTI research.
How Long to Take Them
Clinical trials typically use probiotics for at least 90 days, with outcomes measured during and after the supplementation period. The 12-month trial of L. rhamnosus GR-1 and L. reuteri RC-14 in postmenopausal women showed benefits sustained over that full period. For the L. crispatus vaginal suppository, the trial used a 10-week course. In general, you should expect to use a probiotic consistently for at least three months before evaluating whether it’s helping reduce your UTI frequency.
Probiotics don’t provide a permanent change to your bacterial balance. Once you stop taking them, the introduced strains gradually decline. For people with truly recurrent UTIs (typically defined as three or more per year), longer-term use may be necessary to maintain any protective effect.
What Probiotics Won’t Do
Probiotics are a prevention strategy, not a treatment for an active UTI. If you’re currently experiencing burning, urgency, or cloudy urine, you need antibiotics to clear the infection. Delaying treatment increases the risk of the infection spreading to your kidneys.
The role of probiotics is to reduce how often infections come back, particularly for people stuck in a cycle of repeated UTIs and repeated antibiotic courses. For that specific problem, adding a well-chosen probiotic alongside other preventive habits (staying hydrated, urinating after sex, wiping front to back) is a reasonable approach with a favorable safety profile and a growing, if still incomplete, body of evidence behind it.